{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:38:25Z","timestamp":1791578305784,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.eprac.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T22:55:34Z","timestamp":1658357734000},"page":"1050-1054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Thyroid-Stimulating Antibody\/Thyroid-Stimulating Hormone Receptor Antibody Ratio as a Sensitive Screening Test for Active Graves\u2019 Orbitopathy"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0667-8093","authenticated-orcid":false,"given":"Masayoshi","family":"Nakano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroe","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Koshiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2022.07.007_bib1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.eprac.2022.07.007_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2022.07.007_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves' disease: a meta-analysis and systematic review","volume":"93","author":"Chin","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.eprac.2022.07.007_bib4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2169\/internalmedicine.53.1518","article-title":"Graves' ophthalmopathy: epidemiology and natural history","volume":"53","author":"Hiromatsu","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.eprac.2022.07.007_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/thy.1992.2.299","article-title":"Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy","volume":"2","author":"Hiromatsu","year":"1992","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2022.07.007_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17257-6","article-title":"Quantitative analysis of inflammation in orbital fat of thyroid-associated ophthalmopathy using MRI signal intensity","volume":"7","author":"Higashiyama","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.eprac.2022.07.007_bib7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1148\/radiology.190.3.8115640","article-title":"Extraocular muscles in Graves ophthalmopathy: usefulness of T2 relaxation time measurements","volume":"190","author":"Ohnishi","year":"1994","journal-title":"Radiology"},{"key":"10.1016\/j.eprac.2022.07.007_bib8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1507\/endocrj.EJ16-0165","article-title":"Is modified clinical activity score an accurate indicator of diplopia progression in Graves' orbitopathy patients?","volume":"63","author":"Kim","year":"2016","journal-title":"Endocr J"},{"key":"10.1016\/j.eprac.2022.07.007_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1507\/endocrj.K10E-156","article-title":"Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy","volume":"57","author":"Tachibana","year":"2010","journal-title":"Endocr J"},{"key":"10.1016\/j.eprac.2022.07.007_bib10","series-title":"Treatment Guide for Thyroid-Associated Ophthalmopathy","year":"2020"},{"key":"10.1016\/j.eprac.2022.07.007_bib11","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2022.07.007_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/678194","article-title":"Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: a prospective study","volume":"2015","author":"Kampmann","year":"2015","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.eprac.2022.07.007_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/thy.2000.10.809","article-title":"Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease","volume":"10","author":"Noh","year":"2000","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2022.07.007_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1373\/clinchem.2008.115162","article-title":"Intermethod variability in TSH-receptor antibody measurement: implication for the diagnosis of Graves disease and for the follow-up of Graves ophthalmopathy","volume":"55","author":"Massart","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.eprac.2022.07.007_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1530\/EJE-10-0736","article-title":"Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3'-triiodothyronine-predominant Graves' disease","volume":"164","author":"Ito","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2022.07.007_bib16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1210\/jc.2009-2470","article-title":"A\u00a0novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy","volume":"95","author":"Lytton","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.07.007_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s13317-012-0028-1","article-title":"Blocking type TSH receptor antibodies","volume":"4","author":"Furmaniak","year":"2013","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.eprac.2022.07.007_bib18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1089\/thy.1999.9.769","article-title":"Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease","volume":"9","author":"Yamano","year":"1999","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2022.07.007_bib19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3349\/ymj.2013.54.4.1033","article-title":"Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy","volume":"54","author":"Jang","year":"2013","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.eprac.2022.07.007_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2265.2003.01726.x","article-title":"Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease","volume":"58","author":"Tada","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.eprac.2022.07.007_bib21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-100-3-372","article-title":"Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease","volume":"100","author":"Takamatsu","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2022.07.007_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0507","article-title":"Genes that characterize T3-predominant Graves' thyroid tissues","volume":"168","author":"Matsumoto","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2022.07.007_bib23","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2022.07.007_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.iop.0000235499.34867.85","article-title":"VISA classification for Graves orbitopathy","volume":"22","author":"Dolman","year":"2006","journal-title":"Ophthal Plast Reconstr Surg"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22005663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22005663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:12:25Z","timestamp":1761516745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22005663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1530891X22005663"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.07.007","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid-Stimulating Antibody\/Thyroid-Stimulating Hormone Receptor Antibody Ratio as a Sensitive Screening Test for Active Graves\u2019 Orbitopathy","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}